June 6, 2017
Dr. Steven J. Hoffman appointed Full Professor at York University
CIHR congratulates Dr. Steven J. Hoffman, Scientific Director of the CIHR Institute of Population and Public Health (CIHR-IPPH), on his appointment as a Full Professor in the School of Health Policy and Management and Osgood Hall Law School at York University in Toronto, effective July 1, 2017. Dr. Hoffman will be nominated by York University for a Tier 1 Canada Research Chair in Global Governance and Social Innovation. With this appointment, CIHR-IPPH will transition its headquarters to York University. To learn more about this appointment, please visit the York University news release.
June 2, 2017
Meet the Vanier and Banting Recipients
On May 31, the Vanier Banting Secretariat at CIHR released the list of recipients for the Vanier Scholarships and Banting Fellowships. The awards are Canada's most prestigious awards for doctoral students and post-doctoral fellows. The specialties of these researchers span health sciences, natural sciences and engineering, and social sciences and humanities.
The accomplishments of these researchers are remarkable and their futures are bright:
- Suzanne, a Vanier Scholar who took time away from her studies to volunteer with Europe’s refugee crisis;
- Tasha, another Vanier Scholar, is an indigenous researcher studying education for urban indigenous girls; and
- Travis, a Banting Fellow who researches the role of sexual health clinics in mental health for LGBTQ people.
Take a moment and look at some of the recipients’ topics of research online.
May 2, 2017
CIHR congratulates Dr. Michel Bouvier on receiving the 2017 Julius Axelrod Award in Pharmacology from the American Society for Pharmacology and Experimental Therapeutics.
The award acknowledges Dr. Bouvier’s pioneering research on G-protein coupled receptors, a family of proteins that play a key role in the regulation of a wide range of biological processes and are the target of many drug treatments. It also acknowledges his commitment to mentoring students and post-doctoral fellows in his laboratory.Dr. Bouvier is Chief Executive Officer of the Institute for Research in Immunology and Cancer at Université de Montréal. He is the recipient of a CIHR Foundation Grant.
April 20, 2017
This spring, Dr. Alan Bernstein, the inaugural President of CIHR, received the Henry G. Friesen International Prize in Health Research. This $35,000 annual prize, established in 2005, recognizes the accomplishments of an innovative, international health researcher and leader. In his lab at the Samuel Lunenfeld Institute, Dr. Bernstein identified genes that regulate blood stem cells and also play a role in the development of various cancers, including leukemia. As President of CIHR, Dr. Bernstein implemented the vision for Canada’s new agency for health research as articulated in the CIHR Act. He worked with the scientific directors to deliver a national health research agenda and enable researchers to work together in biomedical, clinical, health services, and population health. He then served as executive director of the Global HIV Vaccine Enterprise in New York, an international alliance of researchers and advocates who collaborate to find an HIV vaccine. Currently, as President of the Canadian Institute for Advanced Research, Dr. Bernstein leads global research programs that connect international researchers who conduct groundbreaking work, such as using artificial intelligence to diagnose diseases. As part of the Henry G. Friesen prize, Dr. Bernstein will deliver lectures this fall to various audiences regarding the advancement of health research and its evolving contributions to society.
April 13, 2017
CIHR remembers Dr. Mark A. Wainberg, OC, OQ, PhD
The Canadian Institutes of Health Research is saddened to learn of the passing of Dr. Mark A. Wainberg, former President of the International AIDS Society.
Dr. Wainberg played a pivotal role in the founding of the Canadian Association for HIV Research, was Scientific Director of the Lady Davis Institute for Medical Research at Montreal's Jewish General Hospital, served as Director of the McGill AIDS Centre, and was a member of the CIHR HIV/AIDS Research Advisory Committee.
Among his many contributions to health research, Dr. Wainberg identified the anti-HIV properties of the drug 3TC, used in the treatment of AIDS, and was at the vanguard of the research that led to the discovery of HIV's drug resistant properties. He also distinguished himself by his ability to simplify and explain key concepts relating to HIV/AIDS, allowing them to be understood by the broader public.
A dedicated advocate of patients' rights, Dr. Wainberg was known throughout the world for his perseverance, integrity, and warmth. While a powerful voice for people living with HIV/AIDS has been silenced, his vision will live on through the countless people he inspired over the years.
On behalf of Canada's health research community, we offer our deepest condolences to Dr. Wainberg's family and friends.
- Date modified: